Daiichi Sankyo begins phase 3 ovarian cancer trial for ENHERTU
Tweet Send to a Friend
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have initiated patient dosing in the DESTINY-Ovarian01 phase 3 trial, evaluating ENHERTU ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
